Atrium Therapeutics, Inc. (RNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.19-2.81%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress ATR 1072 through clinical trials including IND clearance, trial initiation, and data reporting for PRKAG2 syndrome treatment.
Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. Management achieved FDA clearance of the IND for ATR 1072 and launched the Corventis Phase 1/2 trial, planning to enroll about 37 participants with first enrollment expected by end 2026. The trajectory shows delivering on clinical development milestones as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“FDA clearance of IND for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome.”
“Progressed ATR 1072 program toward the clinic with GLP toxicology studies and regulatory discussions.”
File IND application for ATR 1086 in 2027 and initiate IND-enabling studies in 2026, plus select next development candidate.
Stated in 2 of last 2 quarters, management plans to file the IND for ATR 1086 in 2027 with enabling studies starting in 2026. This priority is in early stages with no financial or clinical data yet, so progress is limited but consistent with stated plans.
“File IND application for ATR 1086 in 2027, with IND-enabling studies initiating in 2026.”
“Plan to file IND application for ATR 1086 in 2027, with IND-enabling studies starting in 2026.”
Manage cash resources including milestone payments to support operations through mid-2028.
Stated in 2 of last 2 quarters, management reported cash and investments of $267.8M at 2026-Q1 and $263.9M at 2026-Q2, including a $15M milestone payment from Bristol Myers Squibb. Cash levels remain strong and sufficient to fund operations through mid-2028, indicating delivering on capital allocation priorities.
“Cash, cash equivalents and short-term investments totaled $263.9 million as of June 30, 2026.”
“Cash and cash equivalents were $267.8 million as of March 31, 2026.”
Leverage collaborations such as with Bristol Myers Squibb to advance RNA therapeutics for cardiomyopathies.
Stated in 2 of last 2 quarters, management reported earning milestone payments from Bristol Myers Squibb including $15 million in 2026-Q1 and a second milestone in 2026-Q2. These payments demonstrate progress in strategic partnerships supporting growth in precision cardiology.
“Earned a second milestone payment from Bristol Myers Squibb under global cardiovascular collaboration.”
“Earned $15 million milestone payment from Bristol Myers Squibb for development candidate.”
Complete separation from Avidity Biosciences and operate as an independent public company.
Stated in 2 of last 2 quarters, management completed the separation from Avidity Biosciences and launched as an independent publicly traded company in early 2026. This priority is operationally complete and the company is delivering as an independent entity.
“Company operates independently following separation and spin-off from Avidity Biosciences.”
“Launched as an independent, publicly traded precision cardiology company after separation from Avidity.”
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.